| Co-Chairman: |
|
| 10:00 - 10:05 |
John Betteridge, UK
Klaus Parhofer, DE
|
| 10:05 - 10:20 |
Comprehensive Lipid Management: A Therapeutic Imperative
John Chapman, FR
|
| 10:30 - 10:45 |
Insights into HDL—A Critical Part of the Equation
Phil Barter, AU
|
| 10:55 - 11:10 |
Nicotinic Acid: An Important Player in Achieving
Comprehensive Lipid Management
Marja-Riitta Taskinen, FI
|
| 11:20 - 11:45 |
ER Niacin/Laropiprant: A Novel Approach to Enhancing
Treatment of Dyslipidemia
John Betteridge, UK
|
| 11:55 - 12:55 |
Patient Case Studies Discussion
John Betteridge, UK
Klaus Parhofer, DE
|
| 12:55 - 13:00 |
Closing Remarks
Klaus Parhofer, DE
|
| 13:00 - 14:00 |
Lunch
|
CONFRONTING OBSTACLES TO GLYCEMIC CONTROL IN
TYPE 2 DIABETES: THE ROLE OF SITAGLIPTIN IN CLINICAL PRACTICE
|
| Chairman: |
Bernhard Ludvik, AT
|
| 14:00 - 14:05 |
Welcome and Introduction
Bernhard Ludvik, AT
|
| 14:05 - 14:35 |
Early and Aggressive Treatment of Type 2 Diabetes in a
Post-ACCORD Environment
Stefano Del Prato, IT
|
| 14:45 - 15:15 |
Hypoglycemia: A Barrier to Achieving Glycemic Control
in Patients with Type 2 Diabetes
Steven Davis, US
|
| 15:25 - 15:55 |
Update on Sitagliptin: Clinical Data
Michael Nauck, DE
|
| 16:05 - 16:55 |
A Discussion of Clinical Case Studies: Sitagliptin as
Monotherapy or CombinationTherapy
William Cefalu, US
|
| 16:55 - 17:00 |
Closing Remarks
Bernhard Ludvik, AT
|
Symposia Programme
